BI 1839100 clinical trials

A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough

This study looks at a new medicine called BI 1839100. It's for people with lung conditions like Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) who have a troublesome cough. We want to see if the medicine can reduce coughing and if it's safe to use.